Circulating Tumor Cell Testing Market: By Technology based technologies, Xenotransplantation models, Immunocytochemical technologies, EPISPOT functional in-vitro cell culture),, CTC Analysis), By Application, By End user and Region Forecast 2019-2030
Circulating Tumor Cell Testing Market size was valued at US$ 9.4 billion in 2023 and is poised to grow at a CAGR of 11.7% from 2024 -2030. Circulating Tumor Cell (CTC) Testing is a simple blood test that helps oncologists assess the prognosis of patients with metastatic colorectal, breast, or prostate cancer. The cell search test is the only FDA-approved test for CTC assessment. CTC are the cancer cells that detach from solid tumors and enter the bloodstream. The global market is highly fragmented with small biotech firms holding a chunk of the overall industry share. CTC is very rare that on average only 1 CTC is present in 1 billion blood cells and CTC clusters are even rarer. The recent development of cluster chips has been successful in capturing CTC clusters ranging between 2-17 cells is an important development in the global market.
According to WHO, cancer incidence is projected to rise by 50% to reach 15 million by the end of this decade. This alarming increase in the number of patients necessitates this as a potential treatment approach addressing the growing global burden of the disease. Biotech firms dominate the global market. The players are constantly engaged in R&D in order to develop novel methods to treat cancers. Favorable government initiatives will fuel global market size. For instance, CDC supports nationwide screening programs for control of breast, cervical, and colorectal cancer among low-income women with little or no health insurance.
Study Period
2024-2030Base Year
2023CAGR
11.7%Largest Market
EuropeFastest Growing Market
North-America
Increasing in number of cancer cases and rise in geriatric population are the major factors which are attributing for the growth of the market globally. As per the WHO statistics cancer accounts for 13% of deaths globally every year, moreover 70% increase in cancer incidences is anticipated over the next couple of decades and global geriatric population is anticipated to nearly double from 12% to 22% from 2015 to 2022.
Furthermore, advanced technologies in circulating tumor cell (CTC) testing, improved healthcare expenditure, growing awareness regarding circulating tumor cell (CTC) testing and increased government support are the few more factors which are boosting the growth of market globally. However, stringent regulatory framework, prolonged time of approvals for product launching and cost containment measures are the few factors restraining the growth of the market globally.
North America dominates the global market for due to a large number of aging population and technological advancement in the region, heavy investments in R & D activities along with government support will boost the industry demand over the coming years. The UK market is anticipated to grow rapidly over the forecast timeline due to the rising occurrence of cancer along with increasing acceptance of advanced technology.
Asia is expected to witness high growth in circulating tumor cell (CTC) testing market, due to increasing government initiatives, rising economy, and improvement in healthcare infrastructure in the region. Some of the key driving forces for circulating tumor cell (CTC) testing market in emerging countries are increasing R&D investment, a large pool of patients, and rising government funding.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 9.4 billion |
|
Market CAGR |
11.7% |
|
By Technology |
|
|
By Application |
|
|
By End-User |
|
|
By Region |
|
Download Free Sample Report
The circulating tumor cell ctc testing market size was valued at US$ 9.4 billion in 2023 and is set to grow at a significant CAGR of 11.7% from 2024-2030.
Fluxion Biosciences, Clearbridge BioMedics, Adnagen, Apocell, Advanced Cell Diagnostics, Cynvenio Biosystems
North America is the fastest-growing region for the market
| 1. Executive Summary |
| 2. Global Circulating Tumor Cell (CTC) Testing Market Introduction |
| 2.1.Global Circulating Tumor Cell (CTC) Testing Market - Taxonomy |
| 2.2.Global Circulating Tumor Cell (CTC) Testing Market - Definitions |
| 2.2.1.Technology |
| 2.2.2.Application |
| 2.2.3.End User |
| 2.2.4.Region |
| 3. Global Circulating Tumor Cell (CTC) Testing Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Circulating Tumor Cell (CTC) Testing Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Circulating Tumor Cell (CTC) Testing Market By Technology, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. CTC Detection |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. CTC Enrichment |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. CTC Analysis |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6. Global Circulating Tumor Cell (CTC) Testing Market By Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. EMT biomarkers development |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Cancer stem cell research |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Tumorigenesis research |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Others |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 7. Global Circulating Tumor Cell (CTC) Testing Market By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Diagnostic Centers |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Hospitals |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Ambulatory Surgical Centers |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8. Global Circulating Tumor Cell (CTC) Testing Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9. North America Circulating Tumor Cell (CTC) Testing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.CTC Detection |
| 9.1.2.CTC Enrichment |
| 9.1.3.CTC Analysis |
| 9.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.EMT biomarkers development |
| 9.2.2.Cancer stem cell research |
| 9.2.3.Tumorigenesis research |
| 9.2.4.Others |
| 9.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Diagnostic Centers |
| 9.3.2.Hospitals |
| 9.3.3.Ambulatory Surgical Centers |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10. Europe Circulating Tumor Cell (CTC) Testing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.CTC Detection |
| 10.1.2.CTC Enrichment |
| 10.1.3.CTC Analysis |
| 10.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.EMT biomarkers development |
| 10.2.2.Cancer stem cell research |
| 10.2.3.Tumorigenesis research |
| 10.2.4.Others |
| 10.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Diagnostic Centers |
| 10.3.2.Hospitals |
| 10.3.3.Ambulatory Surgical Centers |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11. Asia Pacific (APAC) Circulating Tumor Cell (CTC) Testing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.CTC Detection |
| 11.1.2.CTC Enrichment |
| 11.1.3.CTC Analysis |
| 11.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.EMT biomarkers development |
| 11.2.2.Cancer stem cell research |
| 11.2.3.Tumorigenesis research |
| 11.2.4.Others |
| 11.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Diagnostic Centers |
| 11.3.2.Hospitals |
| 11.3.3.Ambulatory Surgical Centers |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12. Middle East and Africa (MEA) Circulating Tumor Cell (CTC) Testing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.CTC Detection |
| 12.1.2.CTC Enrichment |
| 12.1.3.CTC Analysis |
| 12.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.EMT biomarkers development |
| 12.2.2.Cancer stem cell research |
| 12.2.3.Tumorigenesis research |
| 12.2.4.Others |
| 12.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Diagnostic Centers |
| 12.3.2.Hospitals |
| 12.3.3.Ambulatory Surgical Centers |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13. Latin America Circulating Tumor Cell (CTC) Testing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.CTC Detection |
| 13.1.2.CTC Enrichment |
| 13.1.3.CTC Analysis |
| 13.2. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.EMT biomarkers development |
| 13.2.2.Cancer stem cell research |
| 13.2.3.Tumorigenesis research |
| 13.2.4.Others |
| 13.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Diagnostic Centers |
| 13.3.2.Hospitals |
| 13.3.3.Ambulatory Surgical Centers |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Fluxion Biosciences (U.S.), |
| 14.2.2.Clearbridge BioMedics (Singapore) |
| 14.2.3.Adnagen (Germany), Apocell (U.S.) |
| 14.2.4.Advanced Cell Diagnostics (U.S.) |
| 14.2.5.Cynvenio Biosystems (U.S.) |
| 14.2.6.Aviva Biosciences (U.S.) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
